Financial Hardship, End-of-Life Health Care Use, and Costs in Patients With Cancer - Top-Institutions - MDSpire

Financial Hardship, End-of-Life Health Care Use, and Costs in Patients With Cancer

  • By

  • Veena Shankaran

  • Li Li

  • Sara Khor

  • Kaiyue Yu

  • C. Natasha Kwendakwema

  • Catherine Fedorenko

  • Karma Kreizenbeck

  • Hiba M. Khan

  • Shannon Kestner

  • Winona Wright

  • Scott Ramsey

  • April 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Health Economics
    • Outcomes Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Health Services Research
    • Palliative Care

  • #3

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Oncology
    • Health Economics
    • Epidemiology

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Health Policy
    • Palliative Care

  • #5

    University of Michigan Rogel Cancer Center
    University of Michigan Rogel Cancer Center

    Ann Arbor, MI

    Key Differentiators

    • Oncology
    • Health Services Research
    • Palliative Care

Original Source(s)

Financial Hardship, End-of-Life Health Care Use, and Costs in Patients With Cancer

  • by Veena Shankaran, Li Li, Sara Khor, Kaiyue Yu, C. Natasha Kwendakwema, Catherine Fedorenko, Karma Kreizenbeck, Hiba M. Khan, Shannon Kestner, Winona Wright, Scott Ramsey

  • April 20, 2026

Related Content

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma